This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
▼
Sunday, May 15, 2016
The cost of drugs is killing us. How can we foster access for all?
The cost of drugs is killing us. How can we foster access for all?
Over the past year, high medicine prices have made the headlines. In the UK, two cancer treatments were dropped because they were deemed too expensive. A US Senate subcommittee criticized pharmaceutical company Gilead for charging $84,000 (£57,000) for a full course of its new hepatitis C treatments and found that fostering broad, affordable access for other drugs was not a major concern for the firm.
No comments:
Post a Comment